2025-10-29 14:32:39
Presenters: Moradi A,1 De Leon J,2 Poehler J,2 Huang P,3 Makino E3
Affiliations: 1Moradi MD, San Diego, CA; 2Pacific Clinical Innovations, Vista, CA; 3Allergan Aesthetics, an AbbVie company, Irvine, CA
Background: Facial injections and microneedling are common aesthetic in-office procedures aimed at addressing deep lines and volume loss as well as inducing collagen and elastin production in the skin. A number of cosmetic skin products have been shown to improve the appearance of the skin and can complement the results of these in-office procedures by targeting global skin parameters not addressed by the procedures themselves. The goal of this study was to evaluate the efficacy and tolerability of a next-generation topical hydrating serum (HCH) in conjunction with facial injections or microneedling to improve the appearance of dull, dry, and rough-looking skin.
Methods: An 8-week, single-center, openlabel study enrolled males and females (≥20- 65 years of age) with moderate to severe lack of dewiness (Grade 4-9), mild to moderate global fine lines and wrinkles (Grade 3-6), and mild to moderate rough skin texture (Grade 3-6) who received a pre-elected aesthetic facial injection within the last 2 to 4 weeks (Group 1) or a pre-elected microneedling procedure (Group 2). Participants applied HCH twice a day on the full face. Endpoints included investigator-assessed dewy hydrated skin, dryness, fine lines and wrinkles (periocular, cheeks, and forehead), and the participant self-assessment questionnaire. The tolerability of HCH was assessed throughout the study.
Results: Of 30 female participants (n=15 per group), 47% had Fitzpatrick Skin Phototype IV. Among the pre-elected injection group, 86% of participants received a neuromodulator in the glabella, forehead, canthus, or crow’s feet area of the face. Within the microneedling group, 93% of participants received a deep procedure (0.8 – 2.4mm in depth). Significant increases on the Dewy Hydrated Skin Scale were observed at weeks 2, 4, and 8 in both groups when compared to baseline (p<0.0005 for both groups). At Weeks 2, 4, and 8 dryness decreased in both the facial injection and microneedling group (39%, 48%, and 80% vs 25%, 29%, and 78%, respectively; p<0.008). Significant decreases in fine lines and wrinkles were observed in the periocular (44% for both), forehead (37% vs 30%), left cheek (49% vs 45%), and right cheek area at week 8 (49% vs 39%, facial injection and microneedling group, respectively; p<0.005 and p<0.02). Participant self-assessments showed high overall improvement in skin hydration (100% vs 93%, facial injection and microneedling group, respectively) and high overall satisfaction with using HCH after an in-office procedure (100% for both groups) at Week 8. HCH was well tolerated, with the majority of tolerability parameters remaining below mild.
Conclusion: HCH is an effective and well tolerated adjuvant when used in combination with facial injections or microneedling to improve mild to severe facial dryness.
Disclosures: AM is a clinical investigator for Allergan Aesthetics, an AbbVie company. JDL and JP have no conflicts to disclose. PH and EM are employees of AbbVie Inc and may own AbbVie stock.
Funding: This study was sponsored by Allergan Aesthetics, an AbbVie company. The design, study conduct, and financial support for the study were provided by Allergan Aesthetics, an AbbVie company. AbbVie participated in the interpretation of data, review, and approval of the publication. Medical writing and editorial assistance were provided by Shenavia Balcom-Luker, PhD, of AbbVie Inc. and funded by AbbVie Inc.
©Matrix Medical Communications. View All Articles.